$AMGN, a biopharma company, hinted at positive results for its weight loss drug MariTide. Analysts are assessing its potential against competitors like $NVO and $LLY. Cathie Wood's Ark Invest bought $3.54M worth of $AMGN shares. Traders shorted $AMGN and bought $LLY and $VKTX.
the new $PFE BD/strategy fella .. <3 him already https://t.co/NKrpM4JNFg
Very interesting that $AMGN also tried N-terminal GLP-1 fusion between GIPR mAb and GLP-1. But looks interfered with GIPR binding (see high IC50) and also had short half-lives. https://t.co/U22c3kwWuf https://t.co/zFDHh6UB1Z
$LLY weaker hands flushed last week on silly $AMGN move It worked both ways by buying $LLY dips and shorting $AMGN big valuation spike https://t.co/V4SQQdF6Wk
$LLY Friday dips paying $AMGN short worked nicely $VKTX will bounce over time
$AMGN stock pumped on no material news. Data not until end of year. Covered my full position now under $300
$LLY calls up nicely from last week. Trimmed Holding full position in common shares
$AMGN covered 50% short position around 302+
$AMGN #update Gap FIll Idea paying #repeatable 300 1st target coming See before/after https://t.co/y9fLVVsTVw https://t.co/lI7v2gYkEH
Last week $AMGN shorted around 315 and bought dips in $LLY $VKTX
$AMGN | Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update Following Friday's purchase, Amgen's weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund. The… https://t.co/sjxm770Ktw
5May: How do analysts assess @Amgen's ability to become the third powerhouse #WeightLoss drug developer after @novonordisk and @EliLillyandCo? Read about $AMGN's MariTide, plus updates on $ADXN, $ANVX, $CTMX, and $EBS in my latest StockWatch for @GENbio: https://t.co/HFAzPciHer
$AMGN Report was meh but teased data on their weight loss drug.... Big gap now, more data soon... another block buster possible here like $LLY https://t.co/jrx0OSvBVk
$AMGN — $LLY $NVO $VKTX For a company as litigious as $AMGN to talk up MariTide interim analysis without revealing any real details as publicly as it did… probably means that early results are even better than they let on. https://t.co/HkeEQu4K7K